Back
LYFE SCIENCES
Project: HERA
NM_004168.4:c.163T>C
p.Tyr55His  ·  SDHA
ACMG/AMP
Starting
Initialising…
0%
Legacy Engine
Processing…
Classification rationale
1

NM_004168.4:c.163T>C (p.Tyr55His) is classified as Benign based on the ACMG/AMP 2015 framework.

PMID:25741868 ↗
2

This variant meets BA1 (stand-alone benign): the allele frequency in the East Asian population is 1.96% in gnomAD v2.1 (391/19,954 alleles, 5 homozygotes) and 2.39% in gnomAD v4.1 (1,074/44,890 alleles, 10 homozygotes), with a gnomAD v4.1 grpmax FAF of 2.27%. An allele frequency exceeding 1% in a general population is inconsistent with a role in rare Mendelian disease.

gnomad_v2 ↗ gnomad_v4 ↗ gnomad_canada ↗
3

Additional benign evidence includes BS1 (East Asian AF well above 0.3%), BS2 (12 homozygotes observed in gnomAD v4.1 in a gene where biallelic loss-of-function causes severe early-onset recessive disease), BP4 (REVEL = 0.392; BayesDel = 0.00237; SpliceAI max delta = 0.03; all predictors converge on a benign interpretation), and BP6 (ClinVar consensus of Benign/Likely benign from 11 clinical laboratories).

gnomad_v2 ↗ gnomad_v4 ↗ spliceai ↗ clinvar ↗
4

No pathogenic criteria are met. PVS1 is not applicable (missense variant). PP3 is not met (in silico predictors favor benign). PM1 is not met (the variant is common in population databases despite lying in the FAD-binding domain). PS4 is not met (the variant is classified as benign across clinical laboratories and observed at appreciable frequency in unaffected populations).

spliceai ↗ gnomad_v2 ↗ gnomad_v4 ↗ clinvar ↗
5

The classification of Benign is driven by BA1, which alone is sufficient to classify a variant as Benign under the ACMG/AMP 2015 combination rules.

PMID:25741868 ↗
Applied criteria
Met
Not met
Not assessed
N/A
Very strong
Strong
Moderate
Supporting
Pathogenic evidence
PVS
PVS1
PS
PS1
PS2
PS3
PS4
PM
PM1
PM2
PM3
PM4
PM5
PM6
PP
PP1
PP2
PP3
PP4
PP5
Benign evidence
BA
BA1
BS
BS1
BS2
BS3
BS4
BP
BP1
BP2
BP3
BP4
BP5
BP6
BP7
PVS1
Rationale
Select a criterion to inspect its explanation.
Evidence used
Gaps remaining
Rule
Publications
Research and evidence
gnomAD v2.1 evidence
v2.1
gnomAD v4.1 evidence
v4.1
01
Population
gnomAD v2.1This variant is present in gnomAD v2.1 (AF= 0.00147924; MAF= 0.14792%, 418/282578 alleles, homozygotes = 6) and has highest observed frequency in the East Asian population (AF= 0.0195951; MAF= 1.95951%, 391/19954 alleles, homozygotes = 5); grpmax FAF= 0.0180621.
gnomAD v4.1This variant is present in gnomAD v4.1 (AF= 0.000769209; MAF= 0.07692%, 1241/1613346 alleles, homozygotes = 12) and has highest observed frequency in the East Asian population (AF= 0.0239252; MAF= 2.39252%, 1074/44890 alleles, homozygotes = 10); grpmax FAF= 0.0227368.
gnomAD CanadaThis variant is present in gnomAD-Canada v1.0 (AF= 0.00124891; MAF= 0.12489%, 23/18416 alleles, homozygotes = 0) and has highest observed frequency in the eas population (AF= 0.0112108; grpmax FAF95= 0.00690997).
ClinVar evidence
02
ClinVar
This variant has been reported in ClinVar as Benign (6 clinical laboratories) and as Likely benign (4 clinical laboratories) and as benign (1 clinical laboratory). (ClinVarID = 353201)
Functional evidence
03
Functional
OncoKB: Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. SDHA, a subunit of succinate dehydrogenase, is frequently altered by amplification in various cancers, including lung and bladder cancers.
In silico evidence
04
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.03). REVEL score = 0.392. BayesDel score = 0.00236504.
COSMIC evidence
05
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV53768747, n = 5 times).
Cancer hotspots evidence
06
Cancer hotspots Not found
This variant does not lie in a statistically significant hotspot.
ResidueY55